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Background: Methylphenidate is the most commonly used stimulant drug for the treatment of attention-deficit/
hyperactivity disorder (ADHD). Research has found that methylphenidate is a “reinforcer” and that individuals with
ADHD also abuse this medication. Nevertheless, the molecular consequences of long-term recreational
methylphenidate use or abuse in individuals with ADHD are not yet fully known.
Methods: Spontaneously hypertensive rats (SHR), the most validated and widely used ADHD animal model, were
pretreated with methylphenidate (5 mg/kg, i.p.) during their adolescence (post-natal day [PND] 42–48) and tested
for subsequent methylphenidate-induced conditioned place preference (CPP) and self-administration. Thereafter, the
differentially expressed genes in the prefrontal cortex (PFC) and striatum of representative methylphenidate-treated
SHRs, which showed CPP to and self-administration of methylphenidate, were analyzed.
Results: Genome-wide transcriptome profiling analyses revealed 30 differentially expressed genes in the PFC, which
include transcripts involved in apoptosis (e.g. S100a9, Angptl4, Nfkbia), transcription (Cebpb, Per3), and neuronal plasticity
(Homer1, Jam2, Asap1). In contrast, 306 genes were differentially expressed in the striatum and among them, 252 were
downregulated. The main functional categories overrepresented among the downregulated genes include those
involved in cell adhesion (e.g. Pcdh10, Ctbbd1, Itgb6), positive regulation of apoptosis (Perp, Taf1, Api5), (Notch3,
Nsbp1, Sik1), mitochondrion organization (Prps18c, Letm1, Uqcrc2), and ubiquitin-mediated proteolysis (Nedd4,
Usp27x, Ube2d2).
Conclusion: Together, these changes indicate methylphenidate-induced neurotoxicity, altered synaptic and
neuronal plasticity, energy metabolism and ubiquitin-dependent protein degradation in the brains of
methylphenidate-treated SHRs, which showed methylphenidate CPP and self-administration. In addition, these
findings may also reflect cognitive impairment associated with chronic methylphenidate use as demonstrated in
preclinical studies. Future studies are warranted to determine the clinical significance of the present findings with
regard to long-term recreational methylphenidate use or abuse in individuals with ADHD.
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Central nervous system (CNS) stimulants (e.g. methyl-
phenidate and amphetamines) are recommended as first
line medications for attention-deficit/hyperactivity disorder
(ADHD [1]. Among the psychostimulants, methylphenidate
is the most commonly prescribed [1]. Methylphenidate
blocks the dopamine transporter (DAT), the key mech-
anism responsible for the removal of extracellular dopa-
mine (DA), thereby elevating extracellular DA levels in
various limbic, striatal, cortical, cerebellar terminal fields
and increasing DA signaling and duration of DA response
[2]. Neuroimaging studies showed that therapeutic doses
of methylphenidate increased DA levels in the striatum
and nucleus accumbens (NAc), a mechanism purportedly
thought to explain methylphenidate-induced improvement
of ADHD symptoms [3,4]. However, in light of the ob-
servation that the effects of methylphenidate are similar
to those exerted by other drugs affecting the CNS (e.g.
addictive drugs such as cocaine or methamphetamine), the
abuse potential of methylphenidate has been suggested [5].
The repeated use of stimulants can elicit adverse effects
in behavior and induce drug-related behaviors such as
sensitization, tolerance or dependence [6-8]. Therefore,
the propensity of long-term methylphenidate treat-
ment to induce drug addiction or dependence in indi-
viduals with ADHD has also been implied. A number
of studies have investigated effects of methylphenidate
treatment on subsequent abuse of other addictive drugs
[9-13]. Unfortunately, however, only a few studies have
sought to determine whether the repeated treatment of
methylphenidate will result in the abuse of the drug itself.
Furthermore, the long-term effects of repeated methyl-
phenidate use in behavior and gene expression remain far
from understood [14]. In particular, there is a dearth of in-
formation on the potential neuronal correlates of long-term
recreational methylphenidate use or abuse in individuals
with ADHD [8,14].
Preclinical studies in animal models have provided an
avenue for identifying the potential molecular neuro-
pathobiology of drug-induced neuroadaptations [15].
Moreover, the use of microarray expression profiling has
aided us in capturing neuroadaptations involving com-
plex changes in gene expression that may underlie the
development of drug addiction [15,16]. The early micro-
array studies have shown that repeated methylphenidate
treatment even at a clinically relevant dose produced
changes in gene regulation in cortical and striatal neurons
which are similar to those of cocaine and amphetamine,
indicating addiction liability of the drug [14]. While identi-
fication of these gene sets represents a significant step, it
is likely that there are other changes that have not been
identified, especially those that result from the behavioral
or cognitive processes associated with methylphenidate
use, in addition to the direct pharmacological effects ofthe drug [17-19]. Indeed, by integrating methylphenidate-
induced gene expression changes with outcomes in
“appropriate” animal models of drug addiction (e.g.
conditioned place preference [CPP] tests and drug
self-administration), we identified a subset of neuronal
development genes, which may also mediate the reinforcing
effect of methylphenidate [19]. We suggested significant
clinical implications of these findings on the abuse of
methylphenidate among “healthy” individuals, as our
studies [19] were conducted in Wistar rats, strain used
to represent the “normal” heterogeneous population.
However, the previous findings could not be general-
ized to individuals with ADHD who are also abusing
methylphenidate, as experiments were not conducted
in “appropriate” ADHD animal models.
To address this issue at the preclinical level and to shed
some light on the potential molecular consequences of
long-term recreational methylphenidate use or abuse
in individuals with ADHD, we analyzed the differentially
expressed genes (DEGs) in the brain of methylphenidate-
pretreated Spontaneously Hypertensive rats (SHRs), which
showed CPP to and self-administration of methylphenid-
ate. The SHR, relative to the normotensive Wistar Kyoto
rat strain, exhibits good face, construct and predictive
validity mimicking the behavioral characteristics observed
in ADHD, and is considered as the most widely used and
validated animal model for this disorder [20,21]. Abnormal-
ities both in the genetic and neurotransmitter functions,
such as those seen in ADHD were also observed in the
SHR [22,23]. Moreover, earlier studies have found increased
reactivity of the SHR to stimulants, opioids, alcohol and
other addictive drugs in comparison with other strains, in-
dicating that the SHR, in general, may be used to investi-
gate the relationship between ADHD and drug addiction
[24]. Most studies on the molecular effects of stimulants
have focused on gene regulation in DA target areas such as
the striatum [25,26]. In this regard, genome-wide tran-
scriptional analyses were performed in the striatum be-
cause this brain region controls reward sensitivity, motor
function and habit learning [27]. Furthermore, prefrontal
cortices (PFC) were also included in these analyses be-
cause they include regions involved in processes relevant
to drug addiction such as compulsive drug taking, and
maintenance of behavioral sensitization [28,29].
Methods
Animals and drug treatment
All experiments were performed in accordance with the
Principles of Laboratory Animal Care (NIH) and the Animal
Care and Use Guidelines of Sahmyook University, Korea.
Male SHRs were purchased from Orient Co. Ltd., a
branch of Charles River Laboratories (Seoul, Korea)
and housed in an environmentally-controlled animal
room (temperature [22 ± 2°C] and humidity [55 ± 5%],
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during drug treatment and conditioned place preference
(CPP) experiments, and individually thereafter during
self-administration tests. After a 1 week of acclimatization,
adolescent (6 weeks old) SHRs were given saline [(1 mg/kg,
intraperitoneal (i.p.), cohort 1] or racemic dl-methylphenidate
(obtained from Hwanin Pharmaceutical Co. Korea), twice
daily [at 9 AM and 9 PM], for 7 days (cohort 2) at a dose
(5 mg/kg, i.p.) that produced a CPP response to the drug
[19,30], and evaluated for subsequent methylphenidate CPP
and self-administration. Another group of SHRs (Control)
was pretreated with saline and given saline only during
all behavioral assays. Methylphenidate pretreatment was
started during adolescence, in view of the findings that
treatment initiation during adolescence increased risk
of polydrug use [31,32], and in light of the observation
that methylphenidate pre-exposure during adolescence
increases behavioral response of rats to the reinforcing
effects of addictive drugs [for review see [8]]. Further-
more, since our goal was to “model” recreational use of
methylphenidate in individuals with ADHD, SHRs were
pretreated with methylphenidate at a dose beyond the
clinically-relevant range (0.5-2 mg/kg,i.p.), and adminis-
tered with methylphenidate intraperitoneally, a method
which is twice as potent as oral methylphenidate admin-
istration in increasing extracellular DA levels [33]. Of
note, while drug treatment was conducted during both
light and dark phases of the light/dark cycle, all behav-
ioral tests were conducted during the light portion of
the day only (between 9 AM and 5 PM).
Conditioned place preference (CPP) tests
CPP tests, conducted a day after the final drug or saline
administration, were performed following the methods
described previously [30,34]. Tests were performed in a
two-compartment CPP apparatus described in previous
studies [30,34]. Animal movement and behavior were
video-recorded and analyzed using the Ethovision
(Noldus, Netherlands) system. The CCP tests consisted of
three phases: habituation and preconditioning (3 days),
conditioning (6 days) and post-conditioning (1 day). After
two days of habituation sessions, initial preference of rats
for one compartment of the CPP box was measured for
15 minutes. The conditioning phase followed (6 days)
during which cohort 1 and 2 rats were injected with
methylphenidate (5 mg/kg, i.p.) and confined to their
initially non-preferred side for 30 min [30,34], and given
saline (1 mg/kg, i.p.) and confined to their preferred side
on alternate days. Meanwhile, rats of the control group re-
ceived saline only during the conditioning days. The post-
conditioning phase followed the next day and the time
spent by each rat in each compartment of the CPP appar-
atus was recorded for 15 min. After the post-conditioning
phase, the shift in place preference was determined. CPPdata were expressed as the difference in time spent in
the drug- or saline-paired compartment during the post
and preconditioning phases. The results were presented
as the means ± SEM and statistical analysis was performed
using unpaired t-tests. A P value of <0.05 was regarded
as significant.
Self-administration tests
The rats that showed robust CPP to methylphenidate
were used for further tests (n = 7-9 rats per group) [19].
Six rats from the control group were also used in this
study. Rats were trained to press a lever for a sucrose pellet
reward and when lever-pressing behaviors were stabilized,
they were implanted with silastic catheters in the right
jugular vein following methods described in our previous
study [34]. Following recovery from surgery, rats underwent
6 days of 2-h methylphenidate or saline (control group)
self-administration under the FR1 schedule. The methods
of the self-administration tests are outlined in our previous
study [34]. Each active lever press resulted in an infusion of
0.1 ml saline (0.9% NaCl), or methylphenidate (0.25 mg/
0.1 ml infusion) [34] for cohort 1 or 2 groups, respectively.
The number of saline or methylphenidate infusions admin-
istered by rats over the 6 days of self-administration was re-
corded. The results are presented as the means ± SEM and
two-way ANOVA was used for data comparison. A P value
of <0.05 was regarded as significant. All statistical analyses
(CPP and self-administration tests) were conducted using
GraphPad Prism Version 5 software (San Diego, CA, USA).
Tissue collection and RNA preparation
One day after the final self-administration session, we
removed the brains of 3 rats from cohort 2 (i.e., those
which showed the most robust self-administration) as
well as 3 rats from the control group for microarray
analyses. We used this time point to eliminate con-
founding results induced by the direct effects of the
drug [19]. After decapitation, the brains were rapidly
removed and placed in ice-cold saline. The striatum
(rostral part of the caudate, putamen and the NAc) and
the prefrontal cortex were removed and immediately
frozen at −70°C. Total RNA was isolated using Trizol
reagent (Invitrogen, Carlsbad, CA, USA) according to the
manufacturer’s instructions. The RNA was further purified
using the RNEasy mini kit (Qiagen Inc.). The total RNA
concentration was determined using NanoDrop ND-1000
Spectrometer (NanoDrop Technologies Inc., Montchanin,
DE, USA). The RNA integrity was assessed using a
BioAnalyzer 2100 (Agilent Technologies, Santa Clara,
CA, USA).
Oligonucleotide microarray analyses
Affymetrix GeneChip microarrays were prepared, hybrid-
ized and scanned by the local authorized Affymetrix service
Table 1 Gene identification numbers for Taqman probes
used in the qRT-PCR analysis










Figure 1 Reinforcing effects of repeated methylphenidate
treatment in spontaneously hypertensive rats (SHRs).
(A) Methylphenidate (MPH) CPP in cohort 1 (saline-pretreated SHR
conditioned with methylphenidate, SAL +MPH) and cohort 2
(methylphenidate-pretreated SHR conditioned methylphenidate,
MPH +MPH) rats. During the conditioning phase of the CPP test, the
rats in both cohorts were administered 5 mg/kg dose of MPH. The
control group received saline only. Each bar represents the mean ± S.E.M.
of the difference in the time spent in the drug- or saline-
(for control group) paired side during the post- and preconditioning
phases. ***P < 0.001, significantly different from the saline-treated
groups. n = 10-12 rats per group. (B) MPH self-administration
shown by saline-treated (SAL +MPH) and methylphenidate-pretreated
(MPH+MPH) SHR. The mean number of methylphenidate infusions
obtained by rats over the 6 days of methylphenidate self-administration
is shown. Each symbol represents the mean ± S.E.M. n = 7-9 animals
per group.
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was converted to cDNA and transcribed into cRNA in
the presence of biotinylated ribonucleotides, according
to standard Affymetrix protocols (Affymetrix ‘Expression
Analysis Technical Manual’, #701021 Rev. 5). Biotin-labeled
aRNA were transcribed in vitro following the Affymetrix
GeneChip manufacturer’s protocol. Hybridization was per-
formed using Affymetrix GeneChip Rat Genome 230 2.0
oligonucleotide arrays (Affymetrix, Santa Clara, CA, USA).
The hybridized probe array was stained and washed with
a GeneChip hybridization, wash and stain kit using the
Fluidics Station 450 (Affymetrix). The stained GeneChip
probe array was scanned with a GeneChip Scanner
3000 + 7G (Affymetrix). The signal intensity of the
gene expression level was calculated using Expression
Console Software, Version 1.1 (Affymetrix) based on
the MAS 5.0 algorithm. The procedure used to select
DEGs was as follows: (i) selection of “present” Affymetrix
probe sets for 3 baseline or treated tissue samples; (ii) se-
lection of “up-regulated” and “down-regulated” Affymetrix
probe sets with comparison signal sample/control ra-
tios >1.65 and <0.6, respectively, and whose values
corresponded to average ratio values at the 2.5% tails
of three microarray histograms; and (iii) selection of
Affymetrix probe sets with simultaneously significant
P values (threshold, 0.05) in the Wilcoxon rank test
when compared with vehicle-treated samples.
Gene ontology analysis
The Database for Annotation, Visualization and Integrated
Discovery (DAVID) v6.7 functional clustering tool was used
to identify over-represented ontologic groups among
the gene expression profiles and to group DEGs into
functional categories [35]. Gene Ontology Biological
Process was selected as the functional annotation category
for this analysis.
Validation of microarray data by qRT-PCR
qRT-PCR was performed to validate microarray data on
selected genes. Briefly, 1 microgram of total RNA, obtained
from samples used for microarrays, was reverse-transcribed
into cDNA using SuperScript TM reverse transcriptase
(Invitrogen), and aliquots were stored at −20°C. The
gene identification number for the TaqMan probes
(Applied Biosystems) used in the qRT-PCR analyses are
shown in Table 1. Rat GAPDH (Applied Biosystems) was
also amplified to normalize the variations in cDNA quan-
tities from different samples. The qRT-PCR reactions were
performed in triplicates, and the qRT-PCR data were rep-
resented as Ct values, where Ct is defined as the threshold
cycle. The relative differences in gene expressions were
quantified using equations from a previously developed
mathematical model [36]. The results are presented as the
means ± SEM, and statistical analysis was performed usingone-way ANOVA followed by Bonferroni’s post-test. A
P value of <0.05 was regarded as significant.
Results
Reinforcing effect of repeated methylphenidate treatment
in SHRs
Figure 1 shows that methylphenidate-CPP was expressed
by methylphenidate-pretreated SHRs conditioned with
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(Figure 1). Saline-pretreated SHRs conditioned with the
drug (cohort 1) also showed CPP to methylphenidate
([t (18) = 5.58, P < 0.001] and the average CPP scores
between cohort 1 and 2 rats did not vary significantly
[t (20) = 0.95, P > 0.05]. Out of the 12 animals in cohort 2,
we selected 9 rats with the highest CPP scores for fur-
ther self-administration tests. Seven rats from cohort 1
(i.e., rats with the highest CPP scores) and 7 rats from
the control group were also chosen for further self-
administration studies. Figure 1B shows the number of
methylphenidate infusions obtained by SHRs. Self-
administration tests showed reinforcing effects of me-
thylphenidate in cohort 2 [F (1,84) = 106.0, P < 0.001]
as well as in cohort 1 SHRs [F (1,72) = 333.4, P < 0.001]
and two-way ANOVA revealed no significant difference
in the rate of responding for methylphenidate infusions
between the two groups [F (1,84) = 0.13, P > 0.05]. In sum-
mary, the findings from both CPP and self-administration
studies indicate reinforcing effect of methylphenidate in
drug-pretreated SHRs.
Transcriptional responses to the reinforcing effect of
repeated methylphenidate treatment in the prefrontal
cortex and striatum of the SHR
With regard to the objective of this study, we analyzed
prefrontal cortical and striatal gene expression chan-
ges in methylphenidate-pretreated SHRs, which showed
CPP to and self-administration of methylphenidate.
Genome-wide transcriptional profiling showed that 30
transcripts were differentially regulated in the PFC
(Table 2), while 306 genes were differentially expressed in
the striatum of cohort 2 SHRs vs. controls (see Additional
file 1: Tables S1A and 1B for complete list of differen-
tially expressed genes in the striatum). Interestingly, a
majority (82%) of the DEGs in the striatum were
downregulated genes (Additional file 2: Table S2). The
differentially expressed genes (DEGs) in the PFC belong
to functional categories such as regulation of apoptosis
(Nfkbia, S100a9, Angptl4), transcription (Cebpb, Dbp,
Per3) and cell migration (Abcc9, Ctgf ) (Table 2). The
main functional categories overrepresented among the
upregulated genes in the striatum include those involved
in synaptic transmission (Grm8, Shank1, Camk2n1,
Pja2), negative regulation of apoptosis (Sap30bp, Apoe,
Nfkbia), transcription (Dbp, Klf2, Neurod2), and others
(Additional file 2: Table S2). Categories overrepre-
sented among the downregulated genes are those asso-
ciated with cell adhesion (Pcdh10, Ctbbd1, Itgb6), positive
regulation of apoptosis (Perp, Taf1, Api5), transcription
(Notch3, Nsbp1, Sik1), mitochondrion organization
(Prps18c, Letm1, Uqcrc2), ubiquitin-mediated proteolysis
(Nedd4, Usp27x, Ube2d2) and others (Additional file 2:
Table S2).qRT-PCR validations of selected differentially expressed genes
qRT-PCR was used to confirm a subset of differentially
expressed genes identified in the microarray studies. The
genes selected for qRT-PCR confirmation were those
representing the major functional gene families among
the downregulated genes. The expression patterns of
Pcdh10 and Ctnnd1, genes associated with cell adhesion
were validated through qRT-PCR (Figure 2). We also con-
firmed microarray results with Perp, Nedd4 and Uqcrc2,
genes associated with apoptosis, ubiquitin-mediated
proteolysis, and mitochondria organization, respectively
(Figure 2). Furthermore, we also found a correlation be-
tween expression patterns predicted by microarrays and
those determined by qRT-PCR analyses for S100a9, Angptl4
and Homer1, DEGs in the PFC of cohort 2 SHRs. These
findings strengthen the reliability of our microarray results.
Discussion
To model recreational methylphenidate use in individ-
uals with ADHD, we subjected SHRs to repeated me-
thylphenidate treatment (7 days, twice daily) at a dose
(5 mg/kg, i.p.) beyond the clinically-relevant range
(0.5-2 mg/kg, i.p.), and tested them for subsequent
methylphenidate CPP and drug self-administration. In
order to shed light on the potential molecular conse-
quences of long-term recreational methylphenidate use or
abuse in individuals with ADHD, we analyzed differentially
expressed genes (DEGs) in the PFC and striatum of
methylphenidate-pretreated SHRs, which showed methyl-
phenidate reinforcement (i.e. CPP to and self-administration
of methylphenidate). The findings from behavioral studies
revealed methylphenidate CPP and acquisition of methyl-
phenidate self-administration in methylphenidate-pretreated
SHRs. Genome-wide analyses in the PFC and striatum
of these rats showed that methylphenidate alters the ex-
pression of a number of genes involved in many functional
systems. We discuss herein some of these important
DEGs whose functions have already been characterized,
and hence a role in methylphenidate reinforcement in
SHRs can be extrapolated.
Previous studies showed that methylphenidate pretreat-
ment at the 5 mg/kg dosage (i.p.) enhanced psychomotor
response to cocaine in other rat strains (e.g. Sprague–
Dawley rats and Wistar rats) [10]. Moreover, pretreatment
at various dosages of methylphenidate also increased
vulnerability to cocaine as well as to other addictive drugs
[8,10,11]. We have previously reported enhancement of
CPP response to methylphenidate in methylphenidate-
pretreated (5 mg/kg, ip., 7 days, twice daily) Wistar rats
[19] indicating the occurrence of behavioral sensitization,
a phenomenon associated with enhanced behavioral re-
sponse to repeated treatment of addictive drugs [37]. Drug-
induced sensitization has been thought to underlie certain
aspects of addiction; in particular, the neuroadaptations that
Table 2 Differentially expressed genes in the prefrontal cortex (PFC) of cohort 2 SHRs relative to controls
A. Upregulated genes
Probe set ID Gene title Gene symbol Mean fold
change
Regulation of apoptosis
1388924_at Angiopoietin-like 4 Angptl4 1.78
1389538_at Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha Nfkbia 1.66
1387125_at S100 calcium binding protein A9 S100a9 4.37
1373302_at Alkaline ceramidase 2 Acer2 2.27
1391791_at Alkaline ceramidase 2 Acer2 1.87
Transcription
1387087_at CCAAT/enhancer binding protein (C/EBP), beta Cebpb 1.78
1387874_at D site of albumin promoter (albumin D-box) binding protein Dbp 2.18
1378745_at Period homolog 3 (Drosophila) Per3 1.68
Protein complex assembly
1389234_at Von Willebrand factor Vwf 2.17
1367553_x_at Hemoglobin, beta /// beta globin minor gene /// beta-globin Hbb /// LOC100134871
/// LOC689064
2.82
1370239_at Hemoglobin alpha, adult chain 2 /// hemoglobin alpha 2 chain Hba-a2 /// LOC360504 1.86
1370240_x_at Hemoglobin alpha, adult chain 2 /// hemoglobin alpha 2 chain Hba-a2 /// LOC360504 1.86
Cell migration
1398265_at ATP-binding cassette, subfamily C (CFTR/MRP), member 9 Abcc9 1.81
1367631_at Connective tissue growth factor Ctgf 1.68
Miscellaneous
1371237_a_at Metallothionein 1a /// transthyretin Mt1a /// Ttr 1.69
1371447_at Placenta-specific 8 Plac8 1.80
1384969_at Collagen, type XXIV, alpha 1 Col24a1 1.70
1387658_at Eukaryotic elongation factor-2 kinase Eef2k 1.69
1379766_at — — 1.66
1381178_at — — 2.15
1386145_at — — 2.23
1389250_at — — 1.71
B. Downregulated genes
1370454_at Homer homolog 1 (Drosophila) Homer1 0.37
1370997_at Homer homolog 1 (Drosophila) Homer1 0.46
1380545_at ArfGAP with SH3 domain, ankyrin repeat and PH domain 1 Asap1 0.58
1393324_at Junctional adhesion molecule 2 Jam2 0.55
1393451_at Centromere protein N Cenpn 0.54
1395309_at — — 0.60
1378507_at — — 0.58
1384410_at — — 0.59
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mediate the maintenance and reinstatement of addiction
[37]. We observed in this study that methylphenidate pre-
treatment produced reinforcing effects in SHRs, however,
we also found comparable CPP scores and similar ratesof methylphenidate self-administration in both saline- and
methylphenidate-pretreated rats (cohort 1 and 2 rats,
respectively). Investigating the mechanism that underlies
differential behavioral responses of strains to the reinforcing
effects of repeated methylphenidate treatment is beyond
Figure 2 The confirmed changes in the prefrontal cortical and striatal gene expression in cohort 2 spontaneously hypertensive rats
(SHRs). qRT-PCR validated the expression of Homer1, S100a9 and Angptl4, differentially expressed genes (DEGs) in the prefrontal cortex (PFC), as
well as Pcdh10, Ctnnd1, Uqcrc2, Nedd4, and Perp, DEGs in the striatum of cohort 2 SHRs. The data represent the expression ratios with respect to
the control group (Con), and the values were normalized to GAPDH. *P < 0.05, **P < 0.01 significantly different from the control groups.
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theless, the present and the previous findings [19] appear to
simulate the reported similarity in the rates of drug abuse
or dependence to psychoactive substances in both ADHD
and non-ADHD controls [39].
In general, our microarray studies revealed transcriptional
changes associated with pharmacological effects of the drug
or consequential to effects of chronic methylphenidate ex-
posure (e.g. genes related with apoptosis, inflammation, etc.),
although these analyses also found some DEGs whose
expression may have been changed in response to the
cognitive or behavioral processes associated with drug
use (e.g. genes involved in neuronal and/or synaptic
plasticity as well as in neuronal development) [[17,19],
for review see [18]]. In the PFC, methylphenidate differ-
entially altered the expression of genes involved in
apoptosis (e.g. S100a9, Angptl4, Nfkbia), transcription
(Cebpb,Per3), and neuronal plasticity (Homer1, Jam2,
Asap1). qRT-PCR validated differential expression patterns
of S100a9, a gene that encodes S100a9, which together
with S100a8 exerts broad apoptotic activities [40]. Psy-
chostimulants, including methylphenidate [41], activate
the production of superoxides [42], inflammatory cells
(astrocytes and microglia), and they in turn have been
shown to release numerous pro-inflammatory factors
and cytokines [43]. Moreover, psychostimulant-induced
increases in synaptic and cytosolic DA levels have been
shown to be neurotoxic due to DA-induced production of
reactive oxygen species (ROS), reactive nitrogen species,hydrogen peroxide and dopamine quinones [44-46].
Therefore, enhanced expression of apoptosis-related
genes in the PFC (as well as in the striatum) of cohort
2 SHRs is consistent with the observed neurotoxic effects
of long-term psychostimulant exposure. Additionally, these
findings may also reflect other previously described
neurotoxic effects of chronic methylphenidate treatment
such as decreased antioxidant defenses promoting periph-
eral oxidative adaptation [47], altered Na+, K+-ATPase ac-
tivity in the cerebrum thereby affecting cellular excitability
[48], downregulation of activity regulated cytoskeletal gene
expression interfering with long-term potentiation and
consolidation of long-term memory [49], as well as drug-
induced cognitive impairment on spatial reference and
working memory tasks [50].
Of note, we observed a larger number of DEGs in the
striatum when compared with the PFC in cohort 2 SHRs
coinciding with the findings of our previous study [19], and
corroborating the previous assumption on the crucial role
of the striatum during compulsive drug use or abuse [51].
Interestingly, a majority of the DEGs in the striatum are
downregulated genes associated with important cellular
functions such as cell adhesion (e.g. Pcdh10, Ctbbd1, Itgb6),
transcription (e.g. Notch3, Nsbp1, Sik1), mitochondrion
organization (e.g. Prps18c, Letm1, Uqcrc2) and ubiquitin-
mediated proteolysis (e.g. Nedd4, Usp27x, Ube2d2). The
expression patterns of representative genes (e.g. Pcdh10,
Ctnd1, Uqcrc2, Nedd4) from the different functional
categories have been validated by confirmatory qRT-PCR
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changes in expression levels of these genes influenced
methylphenidate reinforcement in drug-treated SHRs.
Moreover, further studies are warranted to determine the
contribution of these altered transcripts in the molecular
mechanism of long-term recreational methylphenidate use
or abuse in individuals with ADHD.
The decrease in Pcdh10 gene expression is both a novel
and interesting observation considering the role of cell
adhesion genes in maintaining neuronal and synaptic
connections, and also in neuronal development [52].
Pcdh10, a member of the protocadherin gene family of cell
adhesion molecules (CAMs), codes for a cadherin-related
neuronal receptor involved in the establishment and
function of specific cell-cell connections in the brain
[53]. Furthermore, mutant analysis has demonstrated
that loss of Pcdh10 can influence different aspects of
development and post-natal life [48]. Whereas prior to this
study there has been no experimental literature implicating
the role of Pcdh10 in drug abuse, the involvement of this
gene in a neurodevelopmental disorder, autism spectrum
disorder, has already been reported [54]. Hence, downregu-
lation of Pcdh10 gene expression observed in this study is
an index of altered cell-to-cell communication, which may
also signify disturbances in synaptic or neuronal plasticity
within the striatal complex.
Altered gene expression of Uqcrc2 has also been con-
firmed by qRT-PCR. The Uqcrc2 gene is a component of
the mitochondrial respiratory complex III, which codes
for an enzyme involved in the electron transport chain.
Furthermore, dysregulation of the expression of this gene
has been implicated in some neuropsychiatric disorders
such as bipolar disorder [55]. A previous study reported in-
hibition of mitochondrial respiratory chain complex III in
the striatum as well as other brain regions of adult Wistar
rats exposed to chronic (28 days) treatment of methylphen-
idate [56]. Downregulation of mitochondrial respiratory
complex III (as well that of other complexes) has been
viewed as a compensatory response in order to maintain
energy homeostasis through enhancement of other meta-
bolic systems [56]. Alternatively, it has been assumed to
result from neurotoxic effects of methylphenidate via the
generation of ROS [56]. Further studies are required to
examine this point in detail. Nevertheless, the decrease in
Uqcrc2 expression as observed in this study extends the
previous findings [56], and indicates that methylphenidate
treatment alters brain mitochondrial functions. These find-
ings also suggest disruptions in brain energy metabolism in
methylphenidate-treated and reinforced SHRs, although
additional studies are required to confirm this.
Nedd4 gene expression has also been decreased in the
striatum of cohort 2 SHR. Nedd4 belongs to a family of
ubiquitin ligases, which has been shown to play key roles in
both trafficking and degradation of proteins. In particular,Nedd4 has been hypothesized to maintain target protein at
the plasma membrane by balancing steady state insertion
and retrieval of proteins critical to the development
and neuronal function in the brain [57]. Although fur-
ther studies are required, downregulation of Nedd4 in
this study may indicate disruption in the removal of
misfolded or unwanted proteins causing their accumu-
lation. The pathological consequences of this altered
process in the context of long-term methylphenidate abuse
are still unknown, although accumulation of unnecessary
proteins resulting from a defective ubiquitin dependent
proteolysis has been shown to contribute to aggregation
events, a pathogenic mechanism in several neurobehavioral
and neurodegenerative disorders [58,59]. Furthermore, in
view of the important roles of ubiquitin system in synaptic
growth and function, downregulation of Nedd4 may also
affect synaptic growth and plasticity, contributing to altered
brain function.
Conclusion
Altered expression of genes associated with apoptosis,
cell adhesion, mitochondria organization, ubiquitin-
mediated proteolysis, etc. in the PFC and/or striatum
of methylphenidate-treated SHRs which showed me-
thylphenidate CPP and self-administration indicate
methylphenidate-induced neurotoxicity, alterations in
synaptic and neuronal plasticity, energy metabolism
and ubiquitin-dependent protein degradation. In addition,
these changes may also reflect cognitive impairment as-
sociated with chronic methylphenidate use as demon-
strated in preclinical studies [e.g. [49,50]]. Future studies
should be performed to determine the link between
changes in the expression of these genes and influence
on methylphenidate reinforcement in SHRs. Moreover,
additional studies are warranted to determine the clinical
significance of the findings of this study with regard to
methylphenidate abuse or addiction in individuals with
ADHD. Nevertheless, this study presents new research
directions and interesting topics for further investigation.
For instance, it would be worthwhile to examine molecular
changes that occur in the brains of methylphenidate-
pretreated and methylphenidate-reinforced WKY. Pro-
viding answers to this query will establish whether the
reported gene expression changes are exclusive to SHR and
not possibly due to inbreeding. Furthermore, investigating
gene expression changes in methylphenidate-pretreated
animals which showed less methylphenidate CPP and self-
administration will also provide important information
not only on the mechanisms of methylphenidate abuse in
ADHD individuals, but also on protection against methyl-
phenidate addiction via development of novel targets for
the treatment of methylphenidate or psychostimulant
addiction. Along these lines, complementary findings
can be obtained by comparing gene expression patterns
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and atomoxetine, another widely-used ADHD drug with-
out stimulant-like effects and assumed to be devoid of
abuse liability, in view results from a previous study which
showed differential effects of these drugs in SHRs [60].
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